SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001819790-20-000005
Filing Date
2020-11-25
Accepted
2020-11-24 21:27:19
Documents
62
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tars-20200930.htm   iXBRL 10-Q 1690688
2 EX-31.1 exhibit311.htm EX-31.1 11846
3 EX-31.2 exhibit312.htm EX-31.2 12128
4 EX-32.1 exhibit321.htm EX-32.1 9880
5 EX-32.2 exhibit322.htm EX-32.2 9900
  Complete submission text file 0001819790-20-000005.txt   6039918

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20200930.xsd EX-101.SCH 35261
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT tars-20200930_cal.xml EX-101.CAL 62826
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT tars-20200930_def.xml EX-101.DEF 235365
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20200930_lab.xml EX-101.LAB 449677
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20200930_pre.xml EX-101.PRE 317515
11 EXTRACTED XBRL INSTANCE DOCUMENT tars-20200930_htm.xml XML 847642
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39614 | Film No.: 201346659
SIC: 2836 Biological Products, (No Diagnostic Substances)